摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-3-(2-氟苯基)丙烯酸甲酯 | 104201-65-2

中文名称
(E)-3-(2-氟苯基)丙烯酸甲酯
中文别名
——
英文名称
(E)-methyl 3-(2-fluorophenyl)acrylate
英文别名
methyl (E)-3-(2-fluorophenyl)acrylate;methyl (2E)-3-(2-fluorophenyl)prop-2-enoate;methyl (E)-3-(2-fluorophenyl)prop-2-enoate
(E)-3-(2-氟苯基)丙烯酸甲酯化学式
CAS
104201-65-2
化学式
C10H9FO2
mdl
MFCD03102529
分子量
180.179
InChiKey
HEGMSNMENPDWJB-VOTSOKGWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (E)-3-(2-氟苯基)丙烯酸甲酯sodium hydroxide盐酸羟胺氢溴酸 作用下, 以 甲醇四氯化碳二氯甲烷 为溶剂, 反应 30.0h, 生成 4-(bromomethyl)-5-(2-fluorophenyl)-2-(methoxymethyl)isoxazolin-3-one
    参考文献:
    名称:
    Aryl and cycloalkyl analogues of AMPA: synthetic, pharmacological and stereochemical aspects
    摘要:
    We have previously shown that (RS)-2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid (APPA, 2) is a functional partial agonist at the (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) subtype of excitatory amino acid receptors, reflecting that (S)-APPA is a full agonist and (R)-APPA a competitive antagonist at AMPA receptors. We have now synthesized and pharmacologically characterized (RS)-2-amino-3-[3-hydroxy-5-(2-fluorophenyl)isoxazol-4-yl]propionic acid (2-F-APPA, 5a), 3-F-APPA (5b), 4-F-APPA (5c), (S)-4-F-APPA (6), (R)-4-F-APPA (7), and the fully and partially, respectively, saturated APPA (2) analogues, (RS)-2-amino-3-(3-hydroxy-5-cyclohexylisoxazol-4-yl)propionic acid (5d) and compound 5e containing a 1-cyclohexenyl ring. The absolute stereochemistry of 6 and 7 was established on the basis of comparative circular dichroism studies on 6, 7, and (S)- and (R)-APPA. 4-F-APPA (5c), (S)-4-F-APPA (6), 5d, and 5e were shown to selectively inhibit [H-3]AMPA binding and to activate AMPA receptors. Whereas (S)-4-F-APPA (6) showed full AMPA receptor agonism, (R)-4-F-APPA (7) was an AMPA receptor antagonist. Co-administration of (S)- and (R)-4-F-APPA to the rat cortical wedge preparation produced functional partial AMPA receptor agonism. Semi empirical calculations showed that the magnitude of the torsional angle of the bond connecting the two rings in the series of nonannulated bicyclic AMPA analogues appears to be of importance for the potency and efficacy of these compounds. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(97)10017-7
  • 作为产物:
    描述:
    2-氟苯甲醛正丁基锂 、 chlorobis(ethylene)rhodium(I) dimer 作用下, 以 四氢呋喃正己烷甲苯 为溶剂, 反应 20.25h, 生成 (E)-3-(2-氟苯基)丙烯酸甲酯
    参考文献:
    名称:
    Michael受体与通过铑催化的C–C键活化产生的芳基亲核试剂的氧化偶联
    摘要:
    利用铑催化,通过碳-碳单键活化产生的芳基亲核试剂成功地与迈克尔受体进行了氧化偶联。反应范围涵盖了由喹啉基酮以及一系列电子不足的末端烯烃产生的亲核试剂,说明了碳-碳键活化与合成有用的偶联方法相交的广阔潜力。证明的氧化偶合产生了一系列肉桂基衍生物,其中一些是难以通过常规途径制备的。
    DOI:
    10.1039/c7ob01212h
点击查看最新优质反应信息

文献信息

  • Mizoroki–Heck Reaction of Unstrained Aryl Ketones via Ligand-Promoted C–C Bond Olefination
    作者:Mei-Ling Wang、Hui Xu、Han-Yuan Li、Biao Ma、Zhen-Yu Wang、Xing Wang、Hui-Xiong Dai
    DOI:10.1021/acs.orglett.1c00296
    日期:2021.3.19
    Mizoroki–Heck reaction of unstrained aryl ketone with acrylate/styrene is accomplished via palladium-catalyzed ligand-promoted C–C bond cleavage. Various (hetero)aryl ketones are compatible in the reaction, affording the alkene product in good to excellent yields. Further applications in the late-stage olefination of some drugs, natural products, and fragrance-derived aryl ketones demonstrate the synthetic utility
    未应变的芳基酮与丙烯酸酯/苯乙烯的Mizoroki-Heck反应是通过钯催化的配体促进的C-C键裂解实现的。各种(杂)芳基酮在反应中是相容的,从而以良好至优异的产率提供了烯烃产物。在某些药物,天然产物和香料衍生的芳基酮的后期烯烃聚合中的进一步应用证明了该方案的合成效用。通过采用酮作为导向基团和离去基团二者,1,2- bifunctionalization经由顺序实现邻-C-H的烷基化/本位-Heck烯。
  • [EN] PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉ DE SULFAMATE DE PHÉNYLALKYLE ET COMPOSITION MYORELAXANTE LE CONTENANT
    申请人:BIO PHARM SOLUTIONS CO LTD
    公开号:WO2013187727A1
    公开(公告)日:2013-12-19
    The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for alleviation of muscle spasm, such that it is promising for preventing or treating various diseases associated with muscle spasm.
    本发明涉及新型苯基烷基磺酰胺化合物,一种用于预防或治疗与肌肉痉挛相关疾病的方法。本发明确保增强肌肉松弛活性,这对于缓解肌肉痉挛至关重要,因此有望预防或治疗与肌肉痉挛相关的各种疾病。
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    申请人:——
    公开号:US20020165241A1
    公开(公告)日:2002-11-07
    Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    由化学式(I)表示的化合物及其药学上可接受的盐,可作为NMDA NR2B拮抗剂,用于缓解疼痛。
  • Enantioselective Synthesis of Pyroglutamic Acid Esters from Glycinate via Carbonyl Catalysis
    作者:Jiguo Ma、Qinghai Zhou、Guanshui Song、Yongchang Song、Guoqing Zhao、Kuiling Ding、Baoguo Zhao
    DOI:10.1002/anie.202017306
    日期:2021.5.3
    Direct α‐functionalization of NH2‐free glycinates with relatively weak electrophiles such as α,βunsaturated esters still remains a big challenge in organic synthesis. With chiral pyridoxal 5 d as a carbonyl catalyst, direct asymmetric conjugated addition at the α‐C of glycinate 1 a with α,βunsaturated esters 2 has been successfully realized, to produce various chiral pyroglutamic acid esters 4 in 14–96 %
    用相对较弱的亲电试剂(例如,α,β-不饱和酯)将不含NH 2的甘氨酸直接进行α-官能化仍然是有机合成中的一大挑战。以手性吡ido醛5 d作为羰基催化剂,已成功实现在甘氨酸1a的α-C与α,β-不饱和酯2的直接不对称共轭加成反应,以14-96%的收率生产各种手性焦谷氨酸酯4原位内酰胺化后具有81–97%ee的物质。该反式与顺非对映异构体可以通过色谱法同时获得,并且可以很容易地通过叔丁基去除和随后的Barton转化为手性4取代的吡咯烷-2-酮,例如具有相同绝对构型的阿兹海默氏药物Rolipram(11)。脱羧。
  • [EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
    申请人:TES PHARMA S R L
    公开号:WO2021170658A1
    公开(公告)日:2021-09-02
    The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.
    本公开涉及能够调节NR2F6活性的化合物。本公开的化合物可用于预防及/或治疗与调节NR2F6活性相关疾病和障碍的方法。
查看更多